CLEVELAND, April 29,
2024 /PRNewswire/ -- GenomOncology (GO) revealed
today an upgraded version of GO Pathology Workbench, their software
platform for tertiary analysis and reporting of next generation
sequencing (NGS) and other molecular testing results. This version
includes expanded support for germline testing, reinforcing its
capacity to conduct tertiary analysis across all assays, ranging
from tumor sequencing, hereditary cancer, rare diseases, and all
somatic and germline panels through whole genome analysis. These
advancements optimize processes within molecular laboratories,
empowering them to seamlessly analyze and report any NGS test in a
singular, unified workflow.
The expanded support for germline testing includes additional
variant annotations, including the FDA-recognized ClinGen database.
This release also includes full support for the American College of
Medical Genetics (ACMG) classification system, including automatic
variant classification based on ClinGen, a seamless loading process
for any existing laboratory's classifications, and an efficient
ACMG worksheet tailored for novel variants. The solution includes
additional features that enhance the efficiency of whole exome and
whole genome sequencing analysis, resulting in a single
comprehensive solution that delivers high-quality, efficient
tertiary analysis and reporting across a molecular laboratory's NGS
testing menu.
The upgrades to GO Pathology workbench for germline testing
complement the best-in-class analysis of somatic testing. GO
Pathology Workbench is an end-to-end tertiary analysis solution
that streamlines quality control review, automates variant
classification and tiering using the AMP/ASCO/CAP somatic tiering
system, matches cancer patients to the most relevant clinical
trials and therapies, and produces a fully customizable report.
"The latest enhancements to GO Pathology Workbench for germline
testing will empower laboratories to interpret and report their
entire NGS test menu using a single application, with all cases in
a shared worklist and database. This will increase efficiency, as
well as enable creative approaches to reporting somatic and
germline results for the same patient" said Matt Stachowiak, Vice President of Product
Innovation at GenomOncology.
About GenomOncology
GenomOncology is a software
company that provides the healthcare community with data-driven
insights to improve cancer care. GenomOncology strengthens
precision oncology programs by transforming valuable, but unusable
data, into actionable oncology treatment options and strategic
insights. GenomOncology's Precision Oncology Platform (POP) powers
its comprehensive set of end-to-end software solutions that enhance
decision support. POP combines both proprietary content and public
and licensed data sets with your internal patient data to provide
you with the information necessary to improve patient outcomes.
Learn more at www.genomoncology.com.
Media Contacts
Alysia
Kaplan, Director of Marketing
GenomOncology, LLC
(440) 617-6087
alysia@genomoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genomoncology-introduces-expanded-support-for-germline-testing-in-go-pathology-workbench-302129974.html
SOURCE GenomOncology